Abstract
Hodgkin's lymphoma (HL) is a type of cancer originating in the lymph nodes. The preferred therapy for advanced HL is a combination of chemotherapies including doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). ABVD has been standard therapy for advanced HL. It is generally considered as safe and rarely has been reported to cause acute liver failure. We present a case of 79-year-old woman with HL, who developed acute liver failure secondary to first cycle of ABVD chemotherapy.
Keywords:
chemotherapy; malignant disease and immunosuppression.
© BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Brentuximab Vedotin
-
Chemical and Drug Induced Liver Injury / complications
-
Chemical and Drug Induced Liver Injury / diagnosis*
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Dose-Response Relationship, Drug
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Hodgkin Disease / drug therapy*
-
Humans
-
Immunoconjugates / therapeutic use*
-
Syncope / chemically induced*
-
Treatment Outcome
-
Vinblastine / administration & dosage
-
Vinblastine / adverse effects
Substances
-
Immunoconjugates
-
Bleomycin
-
Vinblastine
-
Dacarbazine
-
Brentuximab Vedotin
-
Doxorubicin